Technical Data
C2392-31H
CD40 Ligand, Soluble, Recombinant, Human (CD40L, CD40-L, hCD40L, CD40LG, CD154, gp39, HIGM1, IGM, IMD3, T-BAM, T-cell Antigen Gp39, TNF-related Activation Protein, TRAP, Tumor Necrosis Factor Ligand Superfamily Member 5, TNFSF5)
50ug
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 149aa of human soluble CD40(CD154) Ligand/TRAP expressed in E.coli is a non-glycosylated, polypeptide chain.

Molecular Weight:
~16.3kD

Biological Activity:
The ED50 as determined by the dose-dependent stimulation of IL-12 & IL-8 induction by PMB (Peripheral Mononuclear) cells was found to be 5-10nug/ml.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 1.1 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of soluble CD40L as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~16.3kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Targeting LFA-1 and CD154 Suppresses the In Vivo Activation and Development of Cytolytic (CD4-Independent) CD8+ T Cells. J Immunol 2005 Dec 15;175(12):7855-7866. 2. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-{gamma}- and CD40L-mediated costimulation. J Leukoc Biol 2005 Dec 5; 3. The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats.
Mol Cell Biochem 2006 Jan;282(1-2):141-6. 4. Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction. Immunology 2005 Dec;116(4):454-63. 5. Evidence for the requirement for CD40-CD154 interactions in resistance to infections with attenuated Salmonella. J Endotoxin Res 2005;11(6):395-9. 6. Preferential Th2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int Immunol 2005 Dec;17(12):1619-29.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.